Glad you brought this up. My thought is the FDA wanted to know what Cytodyns plans are for HIV, since they did not give that to the FDA the first time around.

They basically want to know if we are continuing HIV or not, and if so they want to know how we plan to continue HIV.

My guess is once they know, they can go tell GILD what to do next in the HIV market. I’m kinda being sarcastic, but honestly I wouldn’t be shocked.

You bring up a good point. Why did the FDA ask us these questions. Seems very odd the way it was explained….